• レポートコード:MRC2301B123 • 出版社/出版日:360iResearch / 2022年10月 • レポート形態:英語、PDF、225ページ • 納品方法:Eメール(受注後2-3日) • 産業分類:医療 |
Single User(1名利用、印刷可) | ¥742,350 (USD4,949) | ▷ お問い合わせ |
Enterprise License(企業利用、印刷可) | ¥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
360iリサーチ社の本調査資料では、2021年に485.08百万ドルであった自閉スペクトラム症(ASD)の世界市場規模が、2022年に513.52百万ドルになり、2027年には689.61百万ドルまで、年平均6.03%で拡大すると予測しています。本資料では、世界の自閉スペクトラム症(ASD)市場について調査・分析し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、薬物別(抗けいれん薬、抗精神病薬、選択的セロトニン再取り込み阻害剤 (SSRI))分析、製品タイプ別(アリピプラゾール、バロバプタン、ブメタニド、CM-AT、その他)分析、流通チャネル別(病院、小売薬局)分析、地域別(南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他)分析、競争状況などを掲載しています。また、本書の企業情報には、AbbVie Inc.、Actavis, Inc.、AstraZeneca PLC、Behavioral Innovations, Inc.、Bristol-Myers Squibb、Consern Pharma Private Limited、Coronis Partners Ltd、Curemark, LLC、Eli Lilly and Company、F. Hoffmann-La Roche AG、GW Pharmaceuticals PLC、Hopebridge, LLC、Intra-Cellular Therapies Inc、Janssen Pharmaceuticals, Inc.( Johnson & Johnson Services, Inc)、Merck & Co., Inc、Mylan N.V.、Neurim Pharmaceuticals, Inc、Novartis AG、Oryzon Genomics S.A.、Otsuka Holdings Co., Ltd、Par Sterile Products, LLC、Pediatric Bioscience, Inc.、Pfizer Inc.、Q BioMed Inc、Sangamo Therapeutics, Inc.、Saniona AB、Servier Laboratories Ltd、Sosei Co. Ltd.、Teva Pharmaceutical Industries Ltd.、Yamo Pharmaceuticals LLC、Zynerba Pharmaceuticals Incなどがあります。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界の自閉スペクトラム症(ASD)市場規模:薬物別 - 抗けいれん薬の市場規模 - 抗精神病薬の市場規模 - 選択的セロトニン再取り込み阻害剤 (SSRI)の市場規模 ・世界の自閉スペクトラム症(ASD)市場規模:製品タイプ別 - アリピプラゾールの市場規模 - バロバプタンの市場規模 - ブメタニドの市場規模 - CM-ATの市場規模 - その他製品の市場規模 ・世界の自閉スペクトラム症(ASD)市場規模:流通チャネル別 - 病院チャネルの市場規模 - 小売薬局チャネルの市場規模 ・世界の自閉スペクトラム症(ASD)市場規模:地域別 - 南北アメリカの自閉スペクトラム症(ASD)市場規模 アメリカの自閉スペクトラム症(ASD)市場規模 カナダの自閉スペクトラム症(ASD)市場規模 ブラジルの自閉スペクトラム症(ASD)市場規模 ... - アジア太平洋の自閉スペクトラム症(ASD)市場規模 日本の自閉スペクトラム症(ASD)市場規模 中国の自閉スペクトラム症(ASD)市場規模 インドの自閉スペクトラム症(ASD)市場規模 韓国の自閉スペクトラム症(ASD)市場規模 台湾の自閉スペクトラム症(ASD)市場規模 ... - ヨーロッパ/中東/アフリカの自閉スペクトラム症(ASD)市場規模 イギリスの自閉スペクトラム症(ASD)市場規模 ドイツの自閉スペクトラム症(ASD)市場規模 インドの自閉スペクトラム症(ASD)市場規模 フランスの自閉スペクトラム症(ASD)市場規模 ロシアの自閉スペクトラム症(ASD)市場規模 ... - その他地域の自閉スペクトラム症(ASD)市場規模 ・競争状況 ・企業情報 |
The Global Autism Spectrum Disorders Market size was estimated at USD 485.08 million in 2021 and expected to reach USD 513.52 million in 2022, and is projected to grow at a CAGR 6.03% to reach USD 689.61 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Autism Spectrum Disorders to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Drug, the market was studied across Anticonvulsants, Antipsychotics, and Selective Serotonin Reuptake Inhibitors (SSRIs).
Based on Product Type, the market was studied across Aripiprazole, Balovaptan, Bumetanide, CM-AT, Melatonin, and Risperidone.
Based on Distribution, the market was studied across Hospitals and Retail Pharmacies.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Autism Spectrum Disorders market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Autism Spectrum Disorders Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Autism Spectrum Disorders Market, including AbbVie Inc., Actavis, Inc., AstraZeneca PLC, Behavioral Innovations, Inc., Bristol-Myers Squibb, Consern Pharma Private Limited, Coronis Partners Ltd, Curemark, LLC, Eli Lilly and Company, F. Hoffmann-La Roche AG, GW Pharmaceuticals PLC, Hopebridge, LLC, Intra-Cellular Therapies Inc, Janssen Pharmaceuticals, Inc.( Johnson & Johnson Services, Inc), Merck & Co., Inc, Mylan N.V., Neurim Pharmaceuticals, Inc, Novartis AG, Oryzon Genomics S.A., Otsuka Holdings Co., Ltd, Par Sterile Products, LLC, Pediatric Bioscience, Inc., Pfizer Inc., Q BioMed Inc, Sangamo Therapeutics, Inc., Saniona AB, Servier Laboratories Ltd, Sosei Co. Ltd., Teva Pharmaceutical Industries Ltd., Yamo Pharmaceuticals LLC, and Zynerba Pharmaceuticals Inc.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Autism Spectrum Disorders Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Autism Spectrum Disorders Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Autism Spectrum Disorders Market?
4. What is the competitive strategic window for opportunities in the Global Autism Spectrum Disorders Market?
5. What are the technology trends and regulatory frameworks in the Global Autism Spectrum Disorders Market?
6. What is the market share of the leading vendors in the Global Autism Spectrum Disorders Market?
7. What modes and strategic moves are considered suitable for entering the Global Autism Spectrum Disorders Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of patients with Autism Spectrum Disorders (ASD)
5.1.1.2. Increase in the government-sponsored awareness programs for autism
5.1.2. Restraints
5.1.2.1. Stringent regulations on product approval
5.1.3. Opportunities
5.1.3.1. Growing research & development activities for effective drugs for the treatment of (ASD)
5.1.3.2. Emergence of new autism medications undergoing clinical trials
5.1.4. Challenges
5.1.4.1. Lack of autism specialists to diagnose the disorder
5.2. Cumulative Impact of COVID-19
6. Autism Spectrum Disorders Market, by Drug
6.1. Introduction
6.2. Anticonvulsants
6.3. Antipsychotics
6.4. Selective Serotonin Reuptake Inhibitors (SSRIs)
7. Autism Spectrum Disorders Market, by Product Type
7.1. Introduction
7.2. Aripiprazole
7.3. Balovaptan
7.4. Bumetanide
7.5. CM-AT
7.6. Melatonin
7.7. Risperidone
8. Autism Spectrum Disorders Market, by Distribution
8.1. Introduction
8.2. Hospitals
8.3. Retail Pharmacies
9. Americas Autism Spectrum Disorders Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Autism Spectrum Disorders Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Autism Spectrum Disorders Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis, By Key Player
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion
13. Company Usability Profiles
13.1. AbbVie Inc.
13.1.1. Business Overview
13.1.2. Key Executives
13.1.3. Product & Services
13.2. Actavis, Inc.
13.2.1. Business Overview
13.2.2. Key Executives
13.2.3. Product & Services
13.3. AstraZeneca PLC
13.3.1. Business Overview
13.3.2. Key Executives
13.3.3. Product & Services
13.4. Behavioral Innovations, Inc.
13.4.1. Business Overview
13.4.2. Key Executives
13.4.3. Product & Services
13.5. Bristol-Myers Squibb
13.5.1. Business Overview
13.5.2. Key Executives
13.5.3. Product & Services
13.6. Consern Pharma Private Limited
13.6.1. Business Overview
13.6.2. Key Executives
13.6.3. Product & Services
13.7. Coronis Partners Ltd
13.7.1. Business Overview
13.7.2. Key Executives
13.7.3. Product & Services
13.8. Curemark, LLC
13.8.1. Business Overview
13.8.2. Key Executives
13.8.3. Product & Services
13.9. Eli Lilly and Company
13.9.1. Business Overview
13.9.2. Key Executives
13.9.3. Product & Services
13.10. F. Hoffmann-La Roche AG
13.10.1. Business Overview
13.10.2. Key Executives
13.10.3. Product & Services
13.11. GW Pharmaceuticals PLC
13.11.1. Business Overview
13.11.2. Key Executives
13.11.3. Product & Services
13.12. Hopebridge, LLC
13.12.1. Business Overview
13.12.2. Key Executives
13.12.3. Product & Services
13.13. Intra-Cellular Therapies Inc
13.13.1. Business Overview
13.13.2. Key Executives
13.13.3. Product & Services
13.14. Janssen Pharmaceuticals, Inc.( Johnson & Johnson Services, Inc)
13.14.1. Business Overview
13.14.2. Key Executives
13.14.3. Product & Services
13.15. Merck & Co., Inc
13.15.1. Business Overview
13.15.2. Key Executives
13.15.3. Product & Services
13.16. Mylan N.V.
13.16.1. Business Overview
13.16.2. Key Executives
13.16.3. Product & Services
13.17. Neurim Pharmaceuticals, Inc
13.17.1. Business Overview
13.17.2. Key Executives
13.17.3. Product & Services
13.18. Novartis AG
13.18.1. Business Overview
13.18.2. Key Executives
13.18.3. Product & Services
13.19. Oryzon Genomics S.A.
13.19.1. Business Overview
13.19.2. Key Executives
13.19.3. Product & Services
13.20. Otsuka Holdings Co., Ltd
13.20.1. Business Overview
13.20.2. Key Executives
13.20.3. Product & Services
13.21. Par Sterile Products, LLC
13.21.1. Business Overview
13.21.2. Key Executives
13.21.3. Product & Services
13.22. Pediatric Bioscience, Inc.
13.22.1. Business Overview
13.22.2. Key Executives
13.22.3. Product & Services
13.23. Pfizer Inc.
13.23.1. Business Overview
13.23.2. Key Executives
13.23.3. Product & Services
13.24. Q BioMed Inc
13.24.1. Business Overview
13.24.2. Key Executives
13.24.3. Product & Services
13.25. Sangamo Therapeutics, Inc.
13.25.1. Business Overview
13.25.2. Key Executives
13.25.3. Product & Services
13.26. Saniona AB
13.26.1. Business Overview
13.26.2. Key Executives
13.26.3. Product & Services
13.27. Servier Laboratories Ltd
13.27.1. Business Overview
13.27.2. Key Executives
13.27.3. Product & Services
13.28. Sosei Co. Ltd.
13.28.1. Business Overview
13.28.2. Key Executives
13.28.3. Product & Services
13.29. Teva Pharmaceutical Industries Ltd.
13.29.1. Business Overview
13.29.2. Key Executives
13.29.3. Product & Services
13.30. Yamo Pharmaceuticals LLC
13.30.1. Business Overview
13.30.2. Key Executives
13.30.3. Product & Services
13.31. Zynerba Pharmaceuticals Inc
13.31.1. Business Overview
13.31.2. Key Executives
13.31.3. Product & Services
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing
• 英文レポート名:Autism Spectrum Disorders Market Research Report by Drug, Product Type, Distribution, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19
• 日本語訳:自閉スペクトラム症(ASD)の世界市場予測(~2027年)
• レポートコード:MRC2301B123 ▷ お問い合わせ(見積依頼・ご注文・質問)